Macular Degeneration News and Research

Latest Macular Degeneration News and Research

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

Stem cell technology corrects genetic defect in rare blinding disorder

Researchers have used cutting-edge stem cell technology to correct a genetic defect present in a rare blinding disorder, another step on a promising path that may one day lead to therapies to reverse blindness caused by common retinal diseases such as macular degeneration and retinitis pigmentosa which affect millions of individuals.

16 Jun 2011

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announced today that it has filed for patent protection covering a novel antibody product for Age-related Macular Degeneration (AMD) and other eye disorders.

16 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD).

7 Jun 2011

Silencing two microRNAs may help treat age-related macular degeneration

Blocking two tiny molecules of RNA - a chemical cousin of DNA - appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, UT Southwestern Medical Center researchers have found.

7 Jun 2011

UV-screening sunglasses, contact lenses can protect eyes from aging and disease

Most of us know that UV-blocking sunscreen protects the skin from aging and disease but we don't realize that UV-screening sunglasses and contact lenses can protect eyes from aging and disease, according to a national American Optometric Association survey.

2 Jun 2011

Wills Eye Institute and Thomas Jefferson University create new vision research center

A new vision research center based in Philadelphia will foster regional, national and global collaborations among a diverse group of exceptional clinicians and researchers working to better diagnose, treat and prevent visual diseases.

21 May 2011

Modified vitamin A drug may help prevent age-related macular degeneration

Slowing down the aggregation or "clumping" of vitamin A in the eye may help prevent vision loss caused by macular degeneration, research from Columbia University Medical Center has found.

19 May 2011

Viewpoints: Gingrich fallout; Sebelius, Matsui on Medicare reform; physicians on their rights

The Republican Presidential campaign is off to a slow start, but judging by the last week not slow enough. First Mitt Romney defends his ObamaCare prototype in Massachusetts, and now Newt Gingrich has decided to run against House Republicans on Medicare. They must be loving this at the White House.

18 May 2011

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its licensee, Alimera Sciences, Inc., resubmitted a New Drug Application for the investigational drug ILUVIEN for the treatment of diabetic macular edema (DME) to the U.S. Food and Drug Administration (FDA) on May 12, 2011 to address questions raised in the Complete Response Letter (CRL) Alimera received in December 2010.

16 May 2011

Mary Ann Liebert's peer-reviewed journal highlights latest developments in ocular gene therapy

Disorders of the eye are excellent targets for gene therapy because the ocular environment is readily accessible, relatively easy to monitor, and sequestered from the rest of the body.

10 May 2011

Advanced Cell Technology first quarter net loss decreases to $3.3 million

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today first quarter financial results for the period ended March 31, 2011. The Company reported a loss from operations of $(4.8) million compared to a loss from operations of $(15.0) million in the 2010 first quarter.

9 May 2011

$University of Oregon physicist to design fractal vision devices$

University of Oregon physicist to design fractal vision devices

University of Oregon researcher Richard Taylor is on a quest to grow flowers that will help people who've lost their sight, such as those suffering from macular degeneration, to see again.

6 May 2011

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.

3 May 2011

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

Ellex Medical Lasers Limited (ASX:ELX) today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT™) for the treatment of Early Age-Related Macular Degeneration (AMD).

2 May 2011

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Avastin, Lucentis are equally effective for age-related macular degeneration treatment

Age-related macular degeneration, a disease that damages the retina and can destroy central vision, affects approximately 1.6 million Americans. For the past five years, there has been active debate over treatment options for AMD patients because ophthalmologists have not had accurate data regarding the true efficacy of the most commonly used medication.

29 Apr 2011

Researchers report Avastin is effective as Lucentis for AMD treatment

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration, is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

29 Apr 2011

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.

28 Apr 2011

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

NASDAQ halts Regeneron's common stock

Stem cell technology corrects genetic defect in rare blinding disorder

InNexus files patent protection for new Age-related Macular Degeneration therapeutic

PDL revises revenue guidance for second quarter 2011 to $122M

Bayer HealthCare seeks EU marketing authorization of VEGF Trap-Eye for treatment of wet AMD

Silencing two microRNAs may help treat age-related macular degeneration

UV-screening sunglasses, contact lenses can protect eyes from aging and disease

Wills Eye Institute and Thomas Jefferson University create new vision research center

Modified vitamin A drug may help prevent age-related macular degeneration

Viewpoints: Gingrich fallout; Sebelius, Matsui on Medicare reform; physicians on their rights

pSivida resubmits ILUVIEN NDA to FDA for diabetic macular edema treatment

Mary Ann Liebert's peer-reviewed journal highlights latest developments in ocular gene therapy

Advanced Cell Technology first quarter net loss decreases to $3.3 million

University of Oregon physicist to design fractal vision devices

Paulig Eye Surgery Center provides non-invasive alternative to keratoconus patients

Positive Ellex 2RT data demonstrates efficacy in treatment of early Age-Related Macular Degeneration

Gene therapy approach using CD59 shows promise against AMD: Study

Avastin, Lucentis are equally effective for age-related macular degeneration treatment

Researchers report Avastin is effective as Lucentis for AMD treatment

Molecular Partners completes MP0112 phase I/IIa trials in wet AMD, DME

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in